A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions

Biomaterials

Volumn 77, Issue , 2016, Pages 164-172

  Fong, Eliza L S ^a   Wan, Xinhai ^b   Yang, Jun ^b   Morgado, Micaela ^c   Mikos, Antonios G ^a   Harrington, Daniel A ^c   Navone, Nora M ^b   Farach Carson, Mary C ^a,b,c  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RICE UNIVERSITY   (United States)

Author keywords

Co culture; Hydrogel; Model; Osteoblasts; Patient derived xenograft; Prostate cancer; Three dimensional

Indexed keywords

BIOLOGICAL MATERIALS; BONE; CELL CULTURE; CELLS; CROSSTALK; CYTOLOGY; HYDROGELS; MODELS; OSTEOBLASTS; PATHOLOGY; THREE DIMENSIONAL COMPUTER GRAPHICS; TUMORS; UROLOGY;

CO-CULTURES; FIBROBLAST GROWTH FACTOR; MICROENVIRONMENTS; OSTEOBLASTIC CELLS; OSTEOGENIC PHENOTYPE; PATIENT-DERIVED XENOGRAFT; PROSTATE CANCERS; THREEDIMENSIONAL (3-D);

DISEASES;

DOVITINIB; FIBROBLAST GROWTH FACTOR; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; BENZIMIDAZOLE DERIVATIVE; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYDROGEL; PEPTIDE; QUINOLONE DERIVATIVE; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; STROMA; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE TUMOR; CELL COMMUNICATION; CELL CULTURE TECHNIQUE; CELL LINE; CYTOLOGY; DEVICES; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; SECONDARY; STROMA CELL; TISSUE ENGINEERING; TUMOR CELL CULTURE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; BENZIMIDAZOLES; BONE NEOPLASMS; CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELL LINE; COCULTURE TECHNIQUES; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; HYDROGELS; IN VITRO TECHNIQUES; MALE; MICE; NEOPLASM PROTEINS; OSTEOBLASTS; PEPTIDES; PROSTATIC NEOPLASMS; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; STROMAL CELLS; TISSUE ENGINEERING; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949228115     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.059     Document Type: Article

References (36)

1. Hutchinson L., Kirk R. High drug attrition rates-where are we going wrong?. Nat. Rev. Clin. Oncol. 2011, 8(4):189-190.
2. Begley C.G., Ellis L.M. Drug development: raise standards for preclinical cancer research. Nature 2012, 483(7391):531-533.
3. Zhao X., Liu Z., Yu L., Zhang Y., Baxter P., Voicu H., et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012, 14(5):574-583.
4. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17(11):1514-1520.
5. Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004, 29(3):193-203.
6. Williams S.A., Anderson W.C., Santaguida M.T., Dylla S.J. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab. Invest. 2013, 93(9):970-982.
7. Peng S., Creighton C.J., Zhang Y., Sen B., Mazumdar T., Myers J.N., et al. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J. Transl. Med. 2013, 11:198.
8. Siolas D., Hannon G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013, 73(17):5315-5319.
9. Gao D., Vela I., Sboner A., Iaquinta P.J., Karthaus W.R., Gopalan A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159(1):176-187.
10. Sueblinvong T., Ghebre R., Iizuka Y., Pambuccian S.E., Isaksson Vogel R., Skubitz A.P., et al. Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS One 2012, 7(11):e50519.
11. Kondo J., Endo H., Okuyama H., Ishikawa O., Iishi H., Tsujii M., et al. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(15):6235-6240.
12. Weiswald L.B., Richon S., Validire P., Briffod M., Lai-Kuen R., Cordelieres F.P., et al. Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br. J. Cancer 2009, 101(3):473-482.
13. Dayyani F., Gallick G.E., Logothetis C.J., Corn P.G. Novel therapies for metastatic castrate-resistant prostate cancer. J. Natl. Cancer Inst. 2011, 103(22):1665-1675.
14. Sluka P., Davis I.D. Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat. Rev. Urol. 2013, 10(8):441-451.
15. Sung S.Y., Hsieh C.L., Law A., Zhau H.E., Pathak S., Multani A.S., et al. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008, 68(23):9996-10003.
16. Li Y.M., Sikes R.A., Malaeb B.S., Yeung F., Law A., Graham S.E., et al. Osteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line models. Urologic Oncol.-Semin. Orig. Invest. 2011, 29(6):802-808.
17. Wan X., Corn P.G., Yang J., Palanisamy N., Starbuck M.W., Efstathiou E., et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 2014, 6(252):252ra122.
18. Logothetis C.J., Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 2005, 5(1):21-28.
19. Gurski L.A., Jha A.K., Zhang C., Jia X., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30(30):6076-6085.
20. Xu X., Gurski L.A., Zhang C., Harrington D.A., Farach-Carson M.C., Jia X.Q. Recreating the tumor microenvironment in a bilayer, hyaluronic acid hydrogel construct for the growth of prostate cancer spheroids. Biomaterials 2012, 33(35):9049-9060.
21. Fong E.L., Martinez M., Yang J., Mikos A.G., Navone N.M., Harrington D.A., et al. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol. Pharm. 2014, 11(7):2040-2050.
22. Lei Y., Gojgini S., Lam J., Segura T. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. Biomaterials 2011, 32(1):39-47.
23. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(9):5413-5418.
24. Kim J., Park Y., Tae G., Lee K.B., Hwang S.J., Kim I.S., et al. Synthesis and characterization of matrix metalloprotease sensitive-low molecular weight hyaluronic acid based hydrogels. J. Mater Sci. Mater Med. 2008, 19(11):3311-3318.
25. Li Z.G., Mathew P., Yang J., Starbuck M.W., Zurita A.J., Liu J., et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 2008, 118(8):2697-2710.
26. Shu X.Z., Liu Y.C., Luo Y., Roberts M.C., Prestwich G.D. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules 2002, 3(6):1304-1311.
27. Zhang X., Xu B., Puperi D.S., Yonezawa A.L., Wu Y., Tseng H., et al. Integrating valve-inspired design features into poly(ethylene glycol) hydrogel scaffolds for heart valve tissue engineering. Acta Biomater. 2015, 14:11-21.
28. Lee Y.C., Cheng C.J., Bilen M.A., Lu J.F., Satcher R.L., Yu-Lee L.Y., et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011, 71(15):5194-5203.
29. Weiswald L.B., Richon S., Massonnet G., Guinebretiere J.M., Vacher S., Laurendeau I., et al. A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. Br. J. Cancer 2013, 108(8):1720-1731.
30. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001, 61(14):5652-5659.
31. Fizazi K., Yang J., Peleg S., Sikes C.R., Kreimann E.L., Daliani D., et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 2003, 9(7):2587-2597.
32. Lu Y., Zhang J., Dai J., Dehne L.A., Mizokami A., Yao Z., et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin. Exp. Metastasis 2004, 21(5):399-408.
33. Corn P.G., Wang F., McKeehan W.L., Navone N. Targeting fibroblast growth factor pathways in prostate cancer. Clin. Cancer Res. 2013, 19(21):5856-5866.
34. Valta M.P., Tuomela J., Bjartell A., Valve E., Vaananen H.K., Harkonen P. FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 2008, 123(1):22-31.
35. Sahadevan K., Darby S., Leung H.Y., Mathers M.E., Robson C.N., Gnanapragasam V.J. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J. Pathol. 2007, 213(1):82-90.
36. van Hinsbergh V.W., Rabelink T.J. FGFR1 and the bloodline of the vasculature. Arterioscler. Thromb. Vasc. Biol. 2005, 25(5):883-886.